GQ Bio Therapeutics

GQ Bio Therapeutics GmbH is engaged in developing gene therapies, specifically utilizing a high-capacity adenovirus vector platform. The company, founded in 2012 in Hamburg, Germany, has completed 4 significant deals and is on track for its most recent deal on February 27, 2025.40 mn. It has a recent pivotal event where Pacira Pharmaceuticals, Inc.GQ Bio specializes in pioneering gene therapy solutions through its high-capacity gene therapy vector platform, designed for the efficient delivery of large and multiple genes. This platform underpins the development of transformative medicines targeting chronic and prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio's innovative products primarily serve healthcare providers and research institutions focused on advancing patient outcomes in genetic medicine.GQ Bio's revenue model revolves around the development and commercialization of its gene therapy products, which includes partnerships with pharmaceutical companies and healthcare institutions to facilitate access to its innovative therapies. The firm engages in direct-to-consumer transactions while also establishing B2B relationships with hospitals and clinical research organizations. The transaction structure typically involves licensing agreements, where clients may gain rights to utilize GQ Bio’s proprietary vector technology in their own therapeutic developments.In February 2025, GQ Bio plans to leverage the acquisition by Pacira BioSciences to further integrate its high-capacity adenovirus gene therapy vector platform, enhancing its portfolio in the development of genetic medicines targeting musculoskeletal diseases. The company is focused on launching new gene therapy products aimed at chronic conditions, with plans to expand its market presence in North America and Europe by 2026.

1. Series A

   Oct 22, 2020

   Amount

   $6.4M

   Investors

   Locked

2. Seed

   Nov 12, 2012

   Amount

   Undisclosed

   Investors

   Locked